NFE2L2 and myelodysplastic syndrome: Cytarabine is used to treat high-risk myelodysplastic syndromes (MDSs), and a report suggests that the inhibition of Nrf2 by luteolin or lentiviral shRNA enhanced the efficacy of cytarabine by decreasing levels of Nrf2-targeted DUSP1 protein in myelodysplastic syndrome patients.138